Pytowski B - Search Results

1

Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.

Holash J, Thurston G, Rudge JS, Yancopoulos GD, Adjei AA, Bergers G, Pytowski B, Pegram M, Gordon MS. Holash J, et al. Among authors: pytowski b. Cancer Metastasis Rev. 2006 Jun;25(2):243-52. doi: 10.1007/s10555-006-8504-6. Cancer Metastasis Rev. 2006. PMID: 16770536 Review. No abstract available.

2

Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.

Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K. Laakkonen P, et al. Among authors: pytowski b. Cancer Res. 2007 Jan 15;67(2):593-9. doi: 10.1158/0008-5472.CAN-06-3567. Cancer Res. 2007. PMID: 17234768

3

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.

Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, Bohlen P, Niesvizky R, Rafii S. Vincent L, et al. Among authors: pytowski b. Cancer Res. 2005 Apr 15;65(8):3185-92. doi: 10.1158/0008-5472.CAN-04-3598. Cancer Res. 2005. PMID: 15833849

4

Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.

Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC, Swartz MA. Pytowski B, et al. J Natl Cancer Inst. 2005 Jan 5;97(1):14-21. doi: 10.1093/jnci/dji003. J Natl Cancer Inst. 2005. PMID: 15632376

5

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.

Falcon BL, Chintharlapalli S, Uhlik MT, Pytowski B. Falcon BL, et al. Among authors: pytowski b. Pharmacol Ther. 2016 Aug;164:204-25. doi: 10.1016/j.pharmthera.2016.06.001. Epub 2016 Jun 8. Pharmacol Ther. 2016. PMID: 27288725 Free article. Review.

6

Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.

Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. Roberts N, et al. Among authors: pytowski b. Cancer Res. 2006 Mar 1;66(5):2650-7. doi: 10.1158/0008-5472.CAN-05-1843. Cancer Res. 2006. PMID: 16510584

7

Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis.

Guo R, Zhou Q, Proulx ST, Wood R, Ji RC, Ritchlin CT, Pytowski B, Zhu Z, Wang YJ, Schwarz EM, Xing L. Guo R, et al. Among authors: pytowski b. Arthritis Rheum. 2009 Sep;60(9):2666-76. doi: 10.1002/art.24764. Arthritis Rheum. 2009. PMID: 19714652 Free PMC article.

8

Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.

Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP, Jain RK. Hoshida T, et al. Among authors: pytowski b. Cancer Res. 2006 Aug 15;66(16):8065-75. doi: 10.1158/0008-5472.CAN-06-1392. Cancer Res. 2006. PMID: 16912183

9

Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1).

Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Schwartz JD, et al. Among authors: pytowski b. Cancer. 2010 Feb 15;116(4 Suppl):1027-32. doi: 10.1002/cncr.24789. Cancer. 2010. PMID: 20127948 Free article.

10

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.

Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH. Saif MW, et al. Among authors: pytowski b. Cancer Chemother Pharmacol. 2016 Oct;78(4):815-24. doi: 10.1007/s00280-016-3134-3. Epub 2016 Aug 26. Cancer Chemother Pharmacol. 2016. PMID: 27566701 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters